 The purpose of this study is to estimate the difference in the efficacy between a 16-week treatment regimen of boceprevir BOC in combination with peg-intron alpha 2b P plus ribavirin R BOC PR and a 28-week treatment regimen of BOC PR in previously untreated participants with chronic hepatitis C CHC genotype 1 in Asia who achieve undetectable hepatitis C virus ribonucleic acid HCV RNA. 